Results 61 to 70 of about 278,985 (182)
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
PLoS ONE, 2014 ObjectiveTherapeutic options for Parkinson's disease mainly consist of L-dopa and dopamine agonists. However, in Japan, the product labeling of the ergot dopamine agonists, cabergoline and pergolide, was revised in April 2007 due to the risk of ...
Sachiko Nakaoka +6 more
doaj +1 more source
Pramipexole use and the risk of pneumonia
BMC Neurology, 2012 Background Patients with Parkinson's disease have an elevated risk of pneumonia and randomized trials suggest that this risk may be increased with the dopamine agonist pramipexole.
Ernst Pierre +3 more
doaj +1 more source
New information of dopaminergic agents based on quantum chemistry calculations
Scientific Reports, 2020 Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease ...
Guillermo Goode-Romero +6 more
doaj +1 more source
Highly potent, selective acylguanidine-type histamine H2 receptor agonists: synthesis and structure-activity relationships [PDF]
, 2008 Potent and selective histamine H2 receptor (H2R) agonists are valuable pharmacological tools and might be of therapeutic value as drugs, for example in the treatment of severe congestive heart failure.
Kraus, Anja
core +1 more source
Journal of Pharmacological Sciences, 2010 Several reports have shown that some dopamine receptor ligands modulate the ischemia–reperfusion injury in animal models; however, its underling mechanisms are still unclear. In this study, we sought to establish an in vitro experimental model of hypoxia/
Saori Shimada +5 more
doaj +1 more source
NEW DOPAMINE AGONISTS IN CARDIOVASCULAR THERAPY
, 1992 Dopamine, a naturally occurring catecholamine, has been extensively used in intensive care for many years. Dopamine stimulates different types of adrenergic receptors: alpha-1 and -2, beta-1 and -2, and dopamine-1 and -2.
SMIT, AJ, GIRBES, ARJ, VANVELDHUISEN, DJ
core +1 more source
Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat
, 2002 Mitochondrial bioenergetic defects are involved in neurological disorders associated with neuronal damage in the striatum, such as Huntington's disease and cerebral ischemia.
Nappi G. +3 more
core +1 more source
Do neurologists in Germany adhere to the national Parkinson's disease guideline?
Neuropsychiatric Disease and Treatment, 2011 Sabrina Schröder1, Daniel Kuessner2, Guy Arnold3, York Zöllner4, Eddie Jones5, Marion Schaefer11Institute of Clinical Pharmacology, Charité University Medicine, CCM, Berlin, Germany; 2Basilea Pharmaceutica, Basel, Switzerland;
Sabrina Schröder +3 more
doaj
Parkinson's disease (PD) is characterized by a set of motor symptoms that depend on nigrostriatal dopaminergic degeneration and respond well to pharmacological dopamine replacement using L-DOPA.
Rosqvist, Kristina +6 more
core +1 more source
Dopamine D1 receptor agonists induce penile erections in rats
, 2003 The dopamine receptor agonist apomorphine has been recently introduced in the treatment of erectile dysfunction. While it is well established that dopamine D2-like receptors play a crucial role in this effect, conflicting result are reported in the ...
D'Aquila, Paolo Stefano +9 more
core +1 more source